Heparan sulfate depletion amplifies TNF-α-induced protein leakage in an in vitro model of protein-losing enteropathy

American Journal of Physiology - Gastrointestinal and Liver Physiology

Volumn 288, Issue 5 51-5, 2005, Pages

  Bode, Lars ^a   Eklund, Erik A ^a   Murch, Simon ^b   Freeze, Hudson H ^a  

^a BURNHAM INSTITUTE   (United States)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Congenital disorders of glycosylation; Fontan surgery; Heparin therapy; Intestinal protein loss

Indexed keywords

ALBUMIN; FLUORESCEIN ISOTHIOCYANATE; HEPARANASE; HEPARIN; ILOMASTAT; MATRIX METALLOPROTEINASE INHIBITOR; PLASMA PROTEIN; PROTEOHEPARAN SULFATE; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; BASOLATERAL MEMBRANE; CELL STRAIN CACO 2; CELL STRAIN HT29; CONTROLLED STUDY; ELECTRIC RESISTANCE; FONTAN PROCEDURE; HUMAN; HUMAN CELL; INFLAMMATION; INTESTINE EPITHELIUM CELL; ISOTOPE LABELING; MONOLAYER CULTURE; PRIORITY JOURNAL; PROTEIN GLYCOSYLATION; PROTEIN LOSING GASTROENTEROPATHY; STATISTICAL ANALYSIS; SULFATION;

EID: 17644411447     PISSN: 01931857     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpgi.00461.2004     Document Type: Article

References (37)

1. Becken WL, Busch HJ, and Sylwester DL. Intestinal protein loss in Crohn's disease. Gastroenterology 62: 207-215, 1972.
2. Bruewer M, Luegering A, Kucharzik T, Parkos CA, Madara JL, Hopkins AM, and Nusrat A. Proinflammatory cytokines disrupt epithelial barrier function by apoptosis-independent mechanisms. J Immunol 171: 6164-6172, 2003.
3. Chakravortty D and Kumar KS. Modulation of barrier function of small intestinal epithelial cells by lamina propria fibroblasts in response to lipopolysaccharide: possible role in TNFα in inducing barrier dysfunction. Microbiol Immunol 43: 527-533, 1999.
4. Day R and Forbes A. Heparin. cell adhesion, and pathogenesis of inflammatory bowel disease. Lancet 354: 62-65, 1999.
5. Donnelly JP, Rosenthal A, Castle VP, and Holmes RD. Reversal of protein-losing enteropathy with heparin therapy in three patients with univentricular hearts and Fontan palliation. J Pediatr 130: 474-478, 1997.
6. Eklund E, Broberg K, Westergren-Thorsson G, Bjardahlen A, Hedlund M, and Malmstrom A. Proteoglycan production in disomic and trisomy 7-carrying human synovial cells. Matrix Biol 21: 325-335, 2002.
7. Fink MP. Intestinal epithelial hyperpermeability: update on the pathogenesis of gut mucosal barrier dysfunction in critical illness. Curr Opin Crit Care 9: 143-151, 2003.
8. Fish SM, Proujansky R, and Reenstra WW. Synergistic effects of Interferon gamma and tumour necrosis factor alpha on T84 cell function. Gut 45: 191-198, 1999.
9. Harvima IT, Lappalainen K, Hirvonen MR, Matto M, Kivinen PK, Hyttinen M, Pelkonen J, and Naukkarinen A. Heparin modulates the growth and adherence and augments the growth-inhibitory action of TNF-α on cultured human keratinocytes. J Cell Biochem 92: 372-386, 2004.
10. Kanwar YS, Linker A, and Farquhar MG. Increased permeability of the glomerular basement membrane to ferritin after removal of glycosaminoglycans (heparan sulfate) by enzyme digestion. J Cell Biol 86: 688-693, 1980.
11. Kelly AM, Feldt RH, Driscoll DJ, and Danielson GK. Use of heparin in the treatment of protein-losing enteropathy after fontan operation for complex congenital heart disease. Mayo Clin Proc 73: 777-779, 1998.
12. Kjellen L and Lindahl U. Proteoglycans: structures and interactions. Annu Rev Biochem 60: 443-475, 1991.
13. Klagsbrun M and Baird A. A dual receptor system is required for basic fibroblast growth factor activity. Cell 67: 229-231, 1991.
14. Lantz M, Thysell H, Nilsson E, and Olsson I. On the binding of tumor necrosis factor (TNF) to heparin and the release in vivo of the TNF-binding protein 1 by heparin. J Clin Invest 88: 2026-2031, 1991.
15. Lenz D, Hambsch J, Schneider P, Hausler HJ, Sauer U, Hess J, and Tarnok A. Protein-losing enteropathy in patients with Fontan circulation: is it triggered by infection? Crit Care 7: 185-190, 2003.
16. Marino BS. Outcomes after the Fontan procedure. Curr Opin Pediatr 14: 620-626, 2002.
17. Michell NP, Lalor P, and Langman MJ. Heparin therapy for ulcerative colitis? Effects and mechanisms. Eur J Gastroenterol Hepatol 13: 449-456, 2001.
18. Murch SH, MacDonald TT, Walker-Smith JA, Levin M, Lionetti P, and Klein NJ. Disruption of sulphated glycosaminoglycans in intestinal inflammation. Lancet 341: 711-714, 1993.
19. Murch SH, Winyard PJ, Koletzko S, Wehner B, Cheema HA, Risdon RA, Phillips AD, Meadows N, Klein NJ, and Walker-Smith J. A congenital enterocyte heparan sulphate deficiency with massive albumin loss, secretory diarrhoea, and malnutrition. Lancet 347: 1299-1301, 1996.
20. Neunlist M, Toumi F, Oreschkova T, Denis M, Leborgne J, Laboisse CL, Galmiche JP, and Jarry A. Human ENS regulates the intestinal epithelial barrier permeability and a tight junction-associated protein ZO-1 via V1Pergic pathways. Am J Physiol Gastrointest Liver Physiol 285: G1028-G1036, 2003.
21. Niehues R, Hasilik M, Alton G, Körner C, Schiebe-Sukumar M, Koch HG, Zimmer KP, Wu R, Harms E, Reiter K, von Figura K, Freeze HH, Harms HK, and Marquardt T. Carbohydrate-deficient glycoprotein syndrome type 1b. Phosphomannose isomerase deficiency and mannose therapy. J Clin Invest 101: 1414-1420, 1998.
22. Ostrow A and Rychik J. Investigations into possible mechanisms of protein-losing enteropathy after Fontan operation (Abstract). J Am Coll Cardiol. 2004. In press.
23. Raats CJ, Van Den Born J, and Berden JH. Glomerular heparan sulfate alterations: mechanisms and relevance for proteinuria. Kidney Int 57: 385-400, 2000.
24. Ramage JK, Stanisz A, Scicchitano R, Hunt RH, and Perdue MH. Effect of immunologic reactions on rat intestinal epithelium. Correlation of increased permeability to chromium 51-labeled ethylenediaminetetraacetic acid and ovalbumin during acute inflammation and anaphylaxis. Gastroenterology 94: 1368-1375, 1988.
25. Resta-Lenert S and Barrett KE. Live probiotics protect intestinal epithelial cells from the effects of infection with enteroinvasive Escherichia coli (EIEC). Gut 52: 988-997, 2003.
26. Ruoslahti E and Yamaguchi Y. Proteoglycans as modulators of growth factor activities. Cell 64: 867-869, 1991.
27. Rychik J. Management of protein-losing enteropathy after the Fontan procedure. Semin Thorac Cardiovasc Surg 1: 15-22, 1998.
28. Rychik J and Spray TL. Strategies to treat protein-losing enteropathy. Semin Thorac Cardiovasc Surg 5: 3-11, 2002.
29. Salvestrini C, Myrdal U, Holmgren D, Spray C, Bode L, Freeze H, and Murch S. Focal loss of duodenal enterocyte heparan sulphate proteoglycans may contribute to protein-losing enteropathy after Fontan surgery. World Congress of Pediatric Gastroenterology, Hepatology and Nutrition: Paris, France. J Pediatr Gastroenterol Nutr 39: S278-S279, 2004.
30. Savidge TC, Shmakov AN, Walker-Smith JA, and Phillips AD. Epithelial cell proliferation in childhood enteropathies. Gut 39: 185-193, 1996.
31. Schmitz H, Fromm M, Bentzel CJ, Scholz P, Detjen K, Mankertz J, Bode H, Epple HJ, Riecken EO, and Schulzke JD. Tumor necrosis factor-aα (TNFα) regulates the epithelial barrier in the human intestinal cell line HT-29/B6. J Cell Sci 112: 137-146, 1999.
32. Shimizu T, Nagata S, Fujii T, Takahashi K, Kishiro M, Ohkubo M, Akimoto K, and Yamashiro Y. Enhanced production of interferon-gamma as a possible cause of protein-losing enteropathy after modified Fontan operation. J Pediatr Gastroenterol Nutr 37: 504-507, 2003.
33. Stoeltzing O, Ahmad SA, Liu W, McCarty MF, Wey JS, Parikh AA, Fan F, Reinmuth N, Kawaguchi M, Bucana CD, and Ellis LM. Angiopoietin-1 inhibits vascular permeability, angiogenesis. and growth of hepatic colon cancer tumors. Cancer Rex 63: 3370-3377, 2003.
34. Suenaert P, Bulteel V, Lemmens L, Noman M, Geypens B, Van Assche G, Geboes K, Ceuppens JL, and Rutgeerts P. Anti-tumor necrosis factor treatment restores the gut barrier in Crohn's disease. Am J Gastroenterol 97: 2000-2004, 2002.
35. Therrien J, Webb GD, and Gatzoulis MA. Reversal of protein losing enteropathy with prednisone in adults with modified fontan operations: long term palliation or bridge to cardiac transplantation? Heart 82: 241-243, 1999.
36. Westphal V, Murch S, Kim S, Srikrishna G, Winchester B, Day R, and Freeze HH. Reduced heparan sulfate accumulation in enterocytes contributes to protein-losing enteropathy in a congenital disorder of glycosylation. Am J Pathol 157: 1917-1925, 2000.
37. Yayon A, Klagsbrun M, Esko JD, Leder P, and Ornitz DM. Cell surface, heparin-like molecules are required for binding of basic fibroblast growth factor to its high affinity receptor. Cell 64: 841-848, 1991.